Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5736512 | 0.97 | PPARG (0.43) | TP53GAAPPARGKCNH2DRD2 | |
| SCHEMBL5737263 | 0.88 | KCNH2 (0.46) | PPARGKCNH2DRD2DRD4DRD3 | |
| SCHEMBL5735267 | 0.85 | KCNH2 (0.48) | PPARGKCNH2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5736626 | 0.85 | KDM4E (0.42) | GAAPPARGKCNH2DRD2DRD4 | |
| SCHEMBL5734610 | 0.84 | KCNH2 (0.47) | PPARGKCNH2DRD2DRD4DRD3 | |
| SCHEMBL5735281 | 0.82 | PPARG (0.43) | PPARGKCNH2SMN1; SMN2MCHR1SLC6A2 | |
| SCHEMBL5736356 | 0.81 | PPARG (0.42) | GAAPPARGKCNH2DRD2DRD4 | |
| SCHEMBL5736908 | 0.81 | KCNH2 (0.48) | PPARGKCNH2MCHR1SLC6A2SLC6A4 | |
| SCHEMBL5737364 | 0.81 | PPARG (0.43) | PPARGKCNH2MCHR1SLC6A2SLC6A4 | |
| SCHEMBL5737378 | 0.81 | KCNH2 (0.44) | PPARGKCNH2SMN1; SMN2MCHR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349833-B1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-04-19 | — | — | EP | disclosed |
| EP-1349833-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-08 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | TP53 1060/4885GAA 1534/4885PPARG 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.